Guanylhydrazones useful for treating diseases associated with T cell activation
AssigneeCytokine PharmaSciences, Inc.
InventorsKevin J. Tracey, Pamela Cohen, Michael Bukrinsky, Helena Schmidtmayerova
Life of this patent
Estimating the term…
Abstract
There is disclosed a method for treating diseases and disorders involving T cell activation and HIV-infection using the p38 mitogen activated protein kinase (MAPK) signaling pathway as a target for intervention. There is further disclosed a use for guanylhydrazone-substituted compounds to treat diseases and disorders related to T cell activation and HIV-infection.
Claims9
A method of treating a disorder or disease characterized by T cell activation, comprising administering to a subject an effective amount of a compound having the formula:
- 3
- wherein:
- X2=GhyCH—, GhyCCH3— or H—;
- X1, X′1 and X′2, independently =GhyCH—or GhyCCH3—;
- Z=-NH(CO)NH—, —(C6H4)—, —(C5NH3)— or -A-(CH2)n-A-, n=2-10, which is unsubstituted, mono- or di-C-methyl substituted, or a mono- or di-unsaturated derivative thereof;
- and A=independently —NH(CO)—, —(CO)NH—, —NH(CO)NH—, —NH— or —O— and salts thereof.
A method of treating a disorder or disease characterized by T cell activation, comprising administering to a subject an effective amount of an agent capable of inhibiting gene expression of a component of the p38 MAPK signaling pathway.
Dependencies are inferred from the claim text.